نتائج البحث - "Paul Lorigan"

1

Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy

المصدر: British Journal of Cancer

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c10bbc468c875dc8fdb7ba9d41089227Test
http://europepmc.org/articles/PMC4865968Test

2

Survival of patients with advanced metastatic melanoma: The impact of novel therapies

المؤلفون: Keith T. Flaherty, Paul Lorigan, Claus Garbe, Caroline Robert, James Larkin, Selma Ugurel, Jean-Jacques Grob, Axel Hauschild, Paolo A. Ascierto, Grant A. McArthur, Dirk Schadendorf, Antoni Ribas, Georgina V. Long, Joachim Röhmel

المصدر: Ugurel, S; Röhmel, J; Ascierto, PA; Flaherty, KT; Grob, JJ; Hauschild, A; et al.(2016). Survival of patients with advanced metastatic melanoma: The impact of novel therapies. European Journal of Cancer, 53, 125-134. doi: 10.1016/j.ejca.2015.09.013. UCLA: Retrieved from: http://www.escholarship.org/uc/item/0n7424h8Test

مصطلحات موضوعية: 0301 basic medicine, Oncology, Cancer Research, Skin Neoplasms, Survival, Investigational, Kaplan-Meier Estimate, 0302 clinical medicine, Monoclonal, Molecular Targeted Therapy, Neoplasm Metastasis, Vemurafenib, Melanoma, Cancer, Clinical Trials as Topic, Therapies, Investigational, MEK inhibitor, Antibodies, Monoclonal, 5.1 Pharmaceuticals, 6.1 Pharmaceuticals, 030220 oncology & carcinogenesis, Combination, Mathematik, Public Health and Health Services, Drug Therapy, Combination, Immune checkpoint blockers, Development of treatments and therapeutic interventions, medicine.drug, medicine.medical_specialty, Clinical Trials and Supportive Activities, Oncology and Carcinogenesis, Antineoplastic Agents, Ipilimumab, Antibodies, 03 medical and health sciences, Drug Therapy, Clinical Research, Internal medicine, medicine, Humans, Oncology & Carcinogenesis, Protein Kinase Inhibitors, Survival analysis, business.industry, Evaluation of treatments and therapeutic interventions, Dabrafenib, medicine.disease, Immune checkpoint, Surgery, Clinical trial, 030104 developmental biology, Kinase inhibitors, Therapies, Therapy, business

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6765d164ed98d2ab7cd58a2f932779eTest
https://doi.org/10.1016/j.ejca.2015.09.013Test

3

Ipilimumab in the real world

المصدر: Melanoma Research

مصطلحات موضوعية: Adult, Male, Cancer Research, medicine.medical_specialty, Skin Neoplasms, Salvage therapy, Ipilimumab, treatment outcomes, Dermatology, Cancer Vaccines, Health Services Accessibility, Internal medicine, medicine, Humans, Adverse effect, Melanoma, Survival analysis, Aged, Retrospective Studies, Aged, 80 and over, Salvage Therapy, Performance status, business.industry, expanded access programme, Antibodies, Monoclonal, Retrospective cohort study, Middle Aged, ORIGINAL ARTICLES: Clinical research, medicine.disease, Survival Analysis, United Kingdom, Surgery, Europe, Oncology, Expanded access, Disease Progression, Female, business, Follow-Up Studies, metastatic melanoma, medicine.drug

وصف الملف: application/pdf; text

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::759c34fc8ca97ed132d45c2d3c52c851Test
https://doi.org/10.1097/cmr.0000000000000185Test

4

Adjuvant interferon-α for the treatment of high-risk melanoma: An individual patient data meta-analysis

المصدر: European journal of cancer (Oxford, England : 1990). 82

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a567fa4ebe6ab438ed7f6ea6a3cf707eTest
https://pubmed.ncbi.nlm.nih.gov/28692949Test

5

Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis

المساهمون: Laboratory of Molecullar and Cellular Therapy, Laboratory for Medical and Molecular Oncology, Clinical sciences

المصدر: D'Angelo, S P, Larkin, J, Sosman, J A, Lebbé, C, Brady, B, Neyns, B, Schmidt, H, Hassel, J C, Hodi, F S, Lorigan, P, Savage, K J, Miller, W H, Mohr, P, Marquez-Rodas, I, Charles, J, Kaatz, M, Sznol, M, Weber, J S, Shoushtari, A N, Ruisi, M, Jiang, J & Wolchok, J D 2017, ' Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis ', Journal of Clinical Oncology, vol. 35, no. 2, 28056206, pp. 226-235 . https://doi.org/10.1200/JCO.2016.67.9258Test
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
D'Angelo, S P, Larkin, J, Sosman, J A, Lebbé, C, Brady, B, Neyns, B, Schmidt, H, Hassel, J C, Hodi, F S, Lorigan, P, Savage, K J, Miller, W H, Mohr, P, Marquez-Rodas, I, Charles, J, Kaatz, M, Sznol, M, Weber, J S, Shoushtari, A N, Ruisi, M, Jiang, J & Wolchok, J D 2017, ' Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis ', Journal of Clinical Oncology, vol. 35, no. 2, pp. 226-235 . https://doi.org/10.1200/JCO.2016.67.9258Test

مصطلحات موضوعية: 0301 basic medicine, Oncology, Male, medicine.medical_specialty, Cancer Research, Ipilimumab, Antineoplastic Agents, Malignancy, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Original Reports, Antineoplastic Combined Chemotherapy Protocols, medicine, Journal Article, Humans, Melanoma, Aged, Mucous Membrane, Manchester Cancer Research Centre, business.industry, ResearchInstitutes_Networks_Beacons/mcrc, Mucosal melanoma, Mucous membrane, Antibodies, Monoclonal, medicine.disease, Surgery, 030104 developmental biology, medicine.anatomical_structure, Pooled analysis, Nivolumab, 030220 oncology & carcinogenesis, Cutaneous melanoma, oncology, Female, business, medicine.drug

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c613e275d8ae0f17def04d3d1050065Test
https://research.manchester.ac.uk/en/publications/352ade2e-a1f2-44b3-b39e-21dabc479fb9Test

6

A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanoma

المؤلفون: Omid Hamid, Thomas E. Hutson, Ana Arance, Michele Maio, P. Kellie Turner, Claus Garbe, Peter Mohr, Robert Ilaria, Christopher Kaiser, Axel Hauschild, Jean-Jacques Grob, Pascal Wolter, Marjo Hahka-Kemppinen, Jeeyun Lee, Paul Lorigan, Ilaria Conti

المصدر: Cancer. 120:2016-2024

مصطلحات موضوعية: Cancer Research, medicine.medical_specialty, Leukopenia, Randomization, business.industry, Cancer, Phases of clinical research, Neutropenia, medicine.disease, Gastroenterology, Surgery, Clinical trial, chemistry.chemical_compound, Oncology, Paclitaxel, chemistry, Internal medicine, medicine, medicine.symptom, Adverse effect, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::8e4390c6f2ab41447f8fc6790ed649cbTest
https://doi.org/10.1002/cncr.28635Test

7

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival analysis of KEYNOTE-006

المساهمون: Laboratory of Molecullar and Cellular Therapy, Laboratory of Molecular and Medical Oncology, Clinical sciences

مصطلحات موضوعية: 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, business.industry, Ipilimumab, Pembrolizumab, Surgery, Lower incidence, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, Overall survival, Medicine, business, medicine.drug, Advanced melanoma

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23fc4539892dd1d07be846517f3d2e05Test
https://biblio.vub.ac.be/vubir/pembrolizumab-versus-ipilimumab-for-advanced-melanoma-final-overall-survival-analysis-of-keynote006Test(2e1d8a74-0d96-4455-b3cc-da5df5908b2c).html

8

Treatment patterns and outcomes among patients diagnosed with unresectable stage III or IV melanoma in Europe: A retrospective, longitudinal survey (MELODY study)

المؤلفون: A Dueymes, Alessandro Testori, Christophe Bedane, Michele Maio, Paolo A. Ascierto, Céleste Lebbé, Mark R. Middleton, Cyril Konto, Paul Lorigan, M van Baardewijk

المصدر: European Journal of Cancer. 48:3205-3214

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::649b85aa3ea34f4188cc44100bf76208Test
https://doi.org/10.1016/j.ejca.2012.05.010Test

9

Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer

المساهمون: Pulmonary Medicine

المصدر: Journal of Clinical Oncology, 34(31), 3740-+. American Society of Clinical Oncology
Europe PubMed Central

مصطلحات موضوعية: 0301 basic medicine, Adult, Diarrhea, Male, Cancer Research, medicine.medical_specialty, Lung Neoplasms, Neutropenia, medicine.medical_treatment, Ipilimumab, Kaplan-Meier Estimate, Placebo, Gastroenterology, Carboplatin, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, SDG 3 - Good Health and Well-being, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Lung cancer, Etoposide, Aged, Neoplasm Staging, Aged, 80 and over, Chemotherapy, business.industry, Hazard ratio, Middle Aged, medicine.disease, Small Cell Lung Carcinoma, Surgery, 030104 developmental biology, Treatment Outcome, Oncology, chemistry, 030220 oncology & carcinogenesis, Female, Cisplatin, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33422fcfad4240e726a78a0df7ba7ec9Test
https://pure.eur.nl/en/publications/116017bb-e1ce-4d1a-a62f-33b501e3e0a1Test

10

Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin

المؤلفون: Astra M. Liepa, Patrick Peterson, Martin Reck, Mark A. Socinski, Egbert F. Smit, Nick Thatcher, Susan C. Guba, Paul Lorigan, Ewa Szutowicz-Zielińska, Katherine B. Winfree

المساهمون: Pulmonary medicine, CCA - Quality of life

المصدر: Reck, M, Thatcher, N, Smit, E F, Lorigan, P, Szutowicz-Zielinska, E, Liepa, A M, Winfree, K B, Peterson, P, Guba, S C & Socinski, MA 2012, ' Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin ', Lung Cancer, vol. 78, no. 3, pp. 276-281 . https://doi.org/10.1016/j.lungcan.2012.09.002Test
Lung Cancer, 78(3), 276-281. Elsevier Ireland Ltd

مصطلحات موضوعية: Pulmonary and Respiratory Medicine, Oncology, Adult, Male, Cancer Research, medicine.medical_specialty, Guanine, Lung Neoplasms, Kaplan-Meier Estimate, Pemetrexed, Severity of Illness Index, Disease-Free Survival, Carboplatin, chemistry.chemical_compound, Glutamates, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Multicenter Studies as Topic, Extensive stage, neoplasms, Etoposide, Aged, Neoplasm Staging, Proportional Hazards Models, Randomized Controlled Trials as Topic, Retrospective Studies, Aged, 80 and over, Performance status, Proportional hazards model, business.industry, Hazard ratio, Retrospective cohort study, Middle Aged, Prognosis, Small Cell Lung Carcinoma, Surgery, chemistry, Clinical Trials, Phase III as Topic, Quality of Life, Female, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9505cafea27a93757644da01b0f4aea0Test
https://doi.org/10.1016/j.lungcan.2012.09.002Test

تنقيح النتائج